Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP lifted its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 14.4% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 115,107 shares of the company’s stock after acquiring an additional 14,494 shares during the period. Wellington Management Group LLP’s holdings in Centessa Pharmaceuticals were worth $1,928,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after buying an additional 5,316 shares during the period. Geode Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 68.7% during the third quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock valued at $905,000 after buying an additional 23,058 shares during the last quarter. State Street Corp acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $777,000. Finally, JPMorgan Chase & Co. raised its stake in Centessa Pharmaceuticals by 40.1% in the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company’s stock worth $3,189,000 after acquiring an additional 54,482 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider David M. Chao sold 7,000 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares of the company’s stock, valued at approximately $3,863,370.19. The trade was a 3.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $16.34, for a total transaction of $163,400.00. Following the transaction, the insider now directly owns 134,021 shares in the company, valued at approximately $2,189,903.14. The trade was a 6.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 260,168 shares of company stock valued at $4,309,568 in the last ninety days. 11.59% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Trading Up 2.7 %

Centessa Pharmaceuticals stock opened at $11.57 on Friday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.54 billion, a PE ratio of -7.56 and a beta of 1.53. The stock’s 50 day simple moving average is $15.42 and its two-hundred day simple moving average is $16.11. Centessa Pharmaceuticals plc has a 12 month low of $7.75 and a 12 month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04. Analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CNTA shares. Guggenheim reissued a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $27.71.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.